PD-1

[Clinical Cancer Research] Researchers performed targeted next-generation sequencing, immunohistochemistry for MYC, BCL2, and FN1, and fluorescent multiplex immunohistochemistry for microenvironmental markers in a large cohort of diffuse large B cell lymphoma.

[Cancer Communications] Murine CMT167 lung cancer cells were engineered to express the firefly luciferase gene and implanted orthotopically in the lung of syngeneic mice. Bioluminescence imaging, flow cytometry, and immunohistochemistry were employed to determine response to immunotherapy and function of tumor-infiltrating immune cells.

[HiberCell, Inc.] HiberCell announced a clinical trial collaboration with Merck. This metastatic breast cancer clinical trial evaluates KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with HiberCell’s odetiglucan, a Dectin-1, pattern recognition receptor agonist.

[Nature Communications] Researchers hypothesized that delivery of costimulatory receptor mRNA to tumor-infiltrating T cells will enhance the antitumor effects of antibodies.

[Journal of Cellular and Molecular Medicine] Researchers developed a 6-gene immune-related risk model to predict the survival of patients with lung adenocarcinoma (LUAD) in The Cancer Genome Atlas cohort based on TP53 status, and the predictive ability was confirmed in two independent cohorts.

[Oncogene] Scientists found that the 18fluoro-deoxyglucose positron emission tomography/computed tomography-based markers were positively associated with the expression of programmed cell death ligand 1, pyruvate kinase M2, both of which indicate poor prognosis in patients with pancreatic ductal adenocarcinoma.